Prasco selected as Eli Lilly authorized generics partner for Zyprexa

20 October 2011

Privately-held US drugmaker Prasco Laboratories says it has signed a marketing and distribution agreement with Eli Lilly (NYSE: LLY) to market the authorized generic version of the drug major’s blockbuster schizophrenia and bi-polar disorder agent Zyprexa (olanzapine) tablets and Zyprexa Zydis (olanzapine) orally disintegrating tablets, in the US, where it loses patent protection on October 23.

Prasco will begin distribution of both products on the first ANDA entrant into the market. Prasco will market all six strengths of Olanzapine Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg. Olanzapine Orally Disintegrating Tablets will be available in 5mg, 10mg, 15mg, and 20mg strengths.

Zyprexa, which lost exclusivity in Europe last month, generated third-quarter 2011 sales of $1.18 million for Lilly, of which $563 million came from the USA. The financial terms of the agreement with Prasco were not disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK